Rgene Corporation

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
Innate immune pattern-recognition receptors engaged by beta-glucanPolysaccharide
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
BLEX 404Phase 2Pancreatic Cancer
Est. primary completion 2027-04-30 · NCT03301805 · CT.gov ↗
What to watch
December 2027 (1)
BLEX 404Phase 1/2Nonsquamous Nonsmall Cell Neoplasm of Lung
Est. primary completion 2027-12-31 · NCT05764928 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.